Claymore sells 5.02% stake in Dr. Agarwal's Health Care

Claymore Investments (Mauritius) Pte. Ltd. has reduced its stake in Dr. Agarwal's Health Care by selling 1,59,00,000 equity shares on the open market. The transaction, which crossed the 2% disclosure threshold under SEBI regulations on August 12, 2026, marks a significant reduction in the investor's position.

Following the sale, Claymore's shareholding in Dr. Agarwal's Health Care fell to 1,63,96,300 shares, representing 5.17% of the total voting capital. This is a decline from its pre-sale holding of 3,22,96,300 shares, or 10.19%.

Sale Details

The shares were sold through open market transactions. The seller, Claymore Investments, acts in concert with Arvon Investments Pte. Ltd., which did not participate in this specific sale. Arvon's holding remained unchanged at 3,12,75,470 shares (9.87%).

Metric	Before Sale	Sold	After Sale
Shares Held (Claymore)	3,22,96,300	1,59,00,000	1,63,96,300
Stake % (Claymore)	10.19%	5.02%	5.17%
Combined Holding (Claymore + PAC)	20.06%	5.02%	15.04%

What the Numbers Show

The combined holding of Claymore Investments and its person acting in concert (PAC), Arvon Investments Pte. Ltd., dropped from 20.06% to 15.04% following the transaction. Despite the reduction, the group retains a substantial minority stake in the company, maintaining significant influence without crossing the promoter threshold. No encumbrances or pledges were reported on the shares held by either entity.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.39%	-4.85%	+1.74%	+11.31%	+12.19%	+26.10%

Hyperion Investments Pte. Ltd., a Singapore-based shareholder, sold 24,160,000 equity shares of Dr. Agarwal's Health Care on August 12, 2026. The off-market or open market disposal via stock exchanges reduced its total holding in the healthcare company significantly.

The sale brought Hyperion's stake down from 73,193,988 shares, representing 23.09% of the total voting capital, to 49,033,988 shares, or 15.47%. The diluted shareholding similarly contracted from 22.93% to 15.36%.

Transaction Details

The disclosure was filed with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on August 13, 2026, under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Metric	Before Sale	Sale Details	After Sale
Shares Held	73,193,988	24,160,000 sold	49,033,988
Voting Capital %	23.09%	7.62% reduction	15.47%
Diluted Voting %	22.93%	7.57% reduction	15.36%

Hyperion confirmed that it does not belong to the promoter or promoter group of Dr. Agarwal's Health Care. There were no encumbrances, pledges, liens, or non-disposal undertakings on the shares held by Hyperion before or after the transaction.

What the Numbers Show

The sale represents a substantial reduction in institutional exposure, with Hyperion divesting approximately one-third of its previous holding. The company's total equity share capital remained unchanged at 316,983,028 fully paid-up equity shares of ₹1 each, indicating the transaction was a secondary sale between investors rather than a primary issuance or buyback.